At the news
? MIXEDIMPACT 6/10 8-K filed May 5, 2026 at 08:05 ET
Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), wider than the $44.8M loss in Q1 2025, driven by higher R&D and G&A expenses and a $30.4M non-cash charge from CVR fair value changes. The company highlighted positive Phase 2 data for SPY001 in ulcerative colitis, over-enrollment of the RA sub-study, and a pro forma cash position of $1.18B following a $463M public offering, providing runway into H2 2029. The wider loss and lack of revenue (pre-revenue biotech) make this a neutral-to-bearish financial report, but the strong pipeline progress and extended cash runway are positive offsets.
- Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025, driven by higher R&D ($60.4M vs $41.6M) and G&A ($15.2M vs $11.9M) expenses
- Pro forma cash of $1.18B as of March 31, 2026, including $435.3M net proceeds from April 2026 public offering, providing runway into H2 2029
- Positive topline Phase 2 data for SPY001 in ulcerative colitis: 40% clinical remission, 51% endoscopic improvement, statistically significant RHI reduction
- RA sub-study of SKYWAY Phase 2 trial over-enrolled, topline readout accelerated to Q3 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access